<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02875639</url>
  </required_header>
  <id_info>
    <org_study_id>2015CB554401</org_study_id>
    <nct_id>NCT02875639</nct_id>
  </id_info>
  <brief_title>A Clinical Research of Qi Deficiency and Blood Stasis Syndrome (Different Disease With Syndrome)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhu Mingjun</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Henan University of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this research is to reveal the curative effect mechanism of Yiqihuoxue
      prescription which treat the disease of qi deficiency and blood stasis. And at the same time
      this study also try to confirm yiqi huoxue fang qi deficiency blood stasis treatment of
      coronary heart disease (CHD) heart failure the curative effect and security.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Modern research has shown that the main mechanism of the qi deficiency and blood stasis of
      coronary disease combined with cardiac failure is the disorder Nerve-endocrine-immune network
      mechanism, disorder of energy metabolism, blood coagulation/anticoagulation imbalances,
      vascular endothelial injury and the expression of inflammatory factors and cytokines
      disorder, etc. Some studies have identified that the Chinese traditional medicine of
      supplementing qi and activating blood circulation drugs could adjust the nerve - endocrine -
      immune network, improve endothelial function, improve ventricular remodeling, ameliorate
      heart function, alleviate the clinical symptoms, enhance the quality of life, and so on. This
      study by comparing the curative effect of Yi-Qi Formula, Huoxue prescription and two
      prescription of yiqi huoxue (buyang huanwu decoction and Qishen Yiqi Drop Pill) on improving
      energy metabolism, ameliorating heart function, adjusting the blood coagulation and the
      expression of cell adhesion factor, improving endothelial function, to reveal the curative
      effect mechanism of Yiqihuoxue prescription which treat the disease of qi deficiency and
      blood stasis, and confirm the TCM theory that &quot;Qi and blood are correlated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>N-terminal pronatriuretic peptide（NT-proBNP）</measure>
    <time_frame>0 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>N-terminal pronatriuretic peptide（NT-proBNP）</measure>
    <time_frame>3rd month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>N-terminal pronatriuretic peptide（NT-proBNP）</measure>
    <time_frame>9th month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minnesota heart failure quality of life scale</measure>
    <time_frame>0,3rd,9th month</time_frame>
    <description>baseline, 3 months after treatment and follow-up 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sST2，Galectin3,PT,APTT,FBg,TT,TnT,CK,GLUT-1.GLUT-4,H-FABP</measure>
    <time_frame>0，3rd month</time_frame>
    <description>the expression of these may be related to &quot;Qi&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TXA2,PGI2,CD31,CD18,CD11b,R,K,MA</measure>
    <time_frame>0，3rd month</time_frame>
    <description>the expression of these may be related to &quot;Xue&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hs-CRP,IL-1β,IL-6,TNF-α,ICAM-1,VCAM-1,MCP-1,NO,ET-1</measure>
    <time_frame>0，3rd month</time_frame>
    <description>the expression of these may be related to &quot;Mai&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>0,3rd,9th month</time_frame>
    <description>baseline, 3 months after treatment and follow-up 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac magnetic resonance</measure>
    <time_frame>0，3rd month</time_frame>
    <description>baseline, 3 months after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular ultrasound</measure>
    <time_frame>0，3rd month</time_frame>
    <description>baseline, and after 3 months treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>0，3rd month</time_frame>
    <description>baseline, and after 3 months treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac function classification, NYHA</measure>
    <time_frame>0,1st,Sec,3rd,6th,9th,month</time_frame>
    <description>baseline, 3 months after treatment and follow-up 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ultrasonic cardiogram</measure>
    <time_frame>0,3rd,9th month</time_frame>
    <description>baseline, 3 months after treatment and follow-up 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6MWT distance</measure>
    <time_frame>0,3rd,9th month</time_frame>
    <description>baseline, 3 months after treatment and follow-up 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Traditional Chinese Medicine Syndrome Score Scale (TCMSSS)</measure>
    <time_frame>0,3rd,9th month</time_frame>
    <description>baseline, 3 months after treatment and follow-up 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood and urine routine tests,liver and renal function tests,serum</measure>
    <time_frame>0,3rd,month</time_frame>
    <description>safety evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>electrolytes,electrocardiogram (ECG)</measure>
    <time_frame>0,3rd,month</time_frame>
    <description>safety evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite endpoint</measure>
    <time_frame>1st,3rd,6th,9th, month</time_frame>
    <description>all-cause death, frequency of emergency/re-admission to hospital due to HF, frequency of re-admission due to cardiovascular disease, acute coronary syndrome, severe arrhythmia, cardiac shock, revascularization, stroke, pulmonary embolism and peripheral vascular incidences, etc.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Ischemic Heart Failure</condition>
  <arm_group>
    <arm_group_label>tonifying qi group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tonifying qi group:which treated by a kind of Chinese patent medicine (major components: Huangqi,Dangsheng,and so on)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>activating blood group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>which treated by a kind of Chinese patent medicine (major components: Honghua,Taoren,Danggui，and so on)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>qi and blood group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>which treated by a kind of Chinese patent medicine (major components: Huangqi,Dangsheng，Honghua,Taoren,Danggui，and so on)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QISHEN YIQI DRIPPING PILLS group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>which treated by a kind of Chinese patent medicine (major components: Huangqi,Dangsheng，and so on)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>which treated by the simulation of Chinese patent medicine (major components:excipient)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yiqi prescription</intervention_name>
    <arm_group_label>tonifying qi group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Huoxue prescription</intervention_name>
    <arm_group_label>activating blood group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buyang huanwu decoction</intervention_name>
    <arm_group_label>qi and blood group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QISHEN YIQI DRIPPING PILLS</intervention_name>
    <arm_group_label>QISHEN YIQI DRIPPING PILLS group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 1</intervention_name>
    <description>Placebo 1：a drug which imitated QISHEN YIQI DRIPPING PILLS,but do not have active ingredient,just have the excipient.</description>
    <arm_group_label>tonifying qi group</arm_group_label>
    <arm_group_label>activating blood group</arm_group_label>
    <arm_group_label>qi and blood group</arm_group_label>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 2</intervention_name>
    <description>Placebo 2：a drug which imitated Buyang huanwu decoction,but do not have active ingredient,just have the excipient.</description>
    <arm_group_label>QISHEN YIQI DRIPPING PILLS group</arm_group_label>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 40 to 75;

          2. Patients with ischemic heart failure： LVEF less than or equal to 45% measured by
             echocardiography in modified Simpson method

          3. Qi deficiency and blood stasis syndrome;

          4. New York Heart Association (NYHA) Class II to Ⅲ ;

          5. Submitted informed consent

        Exclusion Criteria:

          1. Combin the pulmonary embolism, or acute coronary syndrome (acs) ,or acute
             cerebrovascular disease;

          2. Combin other heart diseases: valvular heart disease, dilated cardiomyopathy,
             hypertension heart disease, pulmonary heart disease,congenital heart disease;

          3. Hypertension and diabetes patients treated with drugs but not controlled within
             standard limit;

          4. Severe hepatic and renal dysfunction, malnutrition, malignant tumour;

          5. Active tuberculosis or rheumatoid diseases;

          6. Nosohemia, organ transplantation,uremia;

          7. Psychosis and drug abuse;

          8. Allergic to the drugs or one component medicine of the drugs of this study ;

          9. Participated in other trials within 1 month ;

         10. Being pregnant, planning for pregnancy or breastfeeding;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhu M jun</last_name>
    <role>Study Director</role>
    <affiliation>First affiliated hospital, Henan University of Traditional Chinese medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wang Y xia</last_name>
    <role>Principal Investigator</role>
    <affiliation>First affiliated hospital, Henan University of Traditional Chinese medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Li Bin</last_name>
    <role>Principal Investigator</role>
    <affiliation>First affiliated hospital, Henan University of Traditional Chinese medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wang Y xia</last_name>
    <phone>13838571596</phone>
    <email>wyxchzhq@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li Bin</last_name>
    <phone>13633811795</phone>
    <email>libinnvhai@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First affiliated hospital, Henan University of Traditional Chinese medicine</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wang Y xia</last_name>
      <phone>13838571596</phone>
      <email>wyxchzhq@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Li Bin</last_name>
      <phone>13633811795</phone>
      <email>libinnvhai@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013 Oct 15;128(16):e240-327. doi: 10.1161/CIR.0b013e31829e8776. Epub 2013 Jun 5.</citation>
    <PMID>23741058</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2016</study_first_submitted>
  <study_first_submitted_qc>August 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2016</study_first_posted>
  <last_update_submitted>August 17, 2016</last_update_submitted>
  <last_update_submitted_qc>August 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Henan University of Traditional Chinese Medicine</investigator_affiliation>
    <investigator_full_name>Zhu Mingjun</investigator_full_name>
    <investigator_title>Professor,chief physicians,the director of Henan University of Traditional Chinese Medicine</investigator_title>
  </responsible_party>
  <keyword>Ischemic Heart Failure</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>qi deficiency and blood stasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

